Zacks: Analysts Anticipate Iovance Biotherapeutics Inc (NASDAQ:IOVA) Will Post Earnings of -$0.35 Per Share

Analysts expect Iovance Biotherapeutics Inc (NASDAQ:IOVA) to announce earnings of ($0.35) per share for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Iovance Biotherapeutics’ earnings, with estimates ranging from ($0.43) to ($0.18). Iovance Biotherapeutics reported earnings per share of ($0.36) in the same quarter last year, which suggests a positive year-over-year growth rate of 2.8%. The firm is scheduled to report its next quarterly earnings results on Tuesday, November 5th.

On average, analysts expect that Iovance Biotherapeutics will report full year earnings of ($1.38) per share for the current fiscal year, with EPS estimates ranging from ($1.60) to ($0.84). For the next financial year, analysts expect that the firm will report earnings of ($1.54) per share, with EPS estimates ranging from ($2.41) to ($0.59). Zacks’ earnings per share calculations are an average based on a survey of research analysts that that provide coverage for Iovance Biotherapeutics.

Iovance Biotherapeutics (NASDAQ:IOVA) last released its quarterly earnings results on Thursday, August 1st. The biotechnology company reported ($0.38) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.29) by ($0.09).

IOVA has been the topic of a number of recent research reports. Wells Fargo & Co raised their price objective on shares of Iovance Biotherapeutics from $23.00 to $32.00 and gave the company an “outperform” rating in a research note on Thursday, May 23rd. ValuEngine raised shares of Iovance Biotherapeutics from a “buy” rating to a “strong-buy” rating in a research note on Thursday, May 23rd. Zacks Investment Research raised shares of Iovance Biotherapeutics from a “sell” rating to a “hold” rating in a research note on Friday, August 9th. BidaskClub cut shares of Iovance Biotherapeutics from a “buy” rating to a “hold” rating in a research note on Friday, July 26th. Finally, B. Riley set a $24.00 price objective on shares of Iovance Biotherapeutics and gave the company a “buy” rating in a research note on Friday, May 17th. Two investment analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company. The company currently has an average rating of “Buy” and a consensus price target of $28.45.

IOVA stock traded down $0.50 during midday trading on Thursday, reaching $20.02. The company’s stock had a trading volume of 1,322,889 shares, compared to its average volume of 1,447,800. Iovance Biotherapeutics has a 52 week low of $7.26 and a 52 week high of $26.59. The stock has a market capitalization of $2.52 billion, a PE ratio of -15.76 and a beta of 1.81. The company has a debt-to-equity ratio of 0.01, a quick ratio of 12.14 and a current ratio of 12.15. The stock’s 50-day moving average price is $23.98.

Institutional investors and hedge funds have recently bought and sold shares of the business. BlackRock Inc. raised its holdings in shares of Iovance Biotherapeutics by 5.9% during the second quarter. BlackRock Inc. now owns 9,355,972 shares of the biotechnology company’s stock worth $229,410,000 after acquiring an additional 520,445 shares during the period. Vanguard Group Inc. grew its position in shares of Iovance Biotherapeutics by 46.3% in the 2nd quarter. Vanguard Group Inc. now owns 8,491,841 shares of the biotechnology company’s stock valued at $208,220,000 after acquiring an additional 2,688,963 shares during the period. Price T Rowe Associates Inc. MD grew its position in shares of Iovance Biotherapeutics by 72.5% in the 2nd quarter. Price T Rowe Associates Inc. MD now owns 6,023,903 shares of the biotechnology company’s stock valued at $147,706,000 after acquiring an additional 2,531,169 shares during the period. Bank of America Corp DE boosted its holdings in shares of Iovance Biotherapeutics by 48.2% during the 2nd quarter. Bank of America Corp DE now owns 3,084,339 shares of the biotechnology company’s stock worth $75,627,000 after buying an additional 1,002,500 shares during the period. Finally, Northern Trust Corp boosted its holdings in shares of Iovance Biotherapeutics by 0.7% during the 2nd quarter. Northern Trust Corp now owns 1,391,601 shares of the biotechnology company’s stock worth $34,122,000 after buying an additional 9,910 shares during the period. Institutional investors own 95.67% of the company’s stock.

Iovance Biotherapeutics Company Profile

Iovance Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. The company's lead product candidate is lifileucel, an adoptive cell therapy that is in Phase II clinical trial using tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors for the treatment of metastatic melanoma.

Featured Article: Trading Penny Stocks

Get a free copy of the Zacks research report on Iovance Biotherapeutics (IOVA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Iovance Biotherapeutics (NASDAQ:IOVA)

Receive News & Ratings for Iovance Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iovance Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.